vs

Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and COMMVAULT SYSTEMS INC (CVLT). Click either name above to swap in a different company.

COMMVAULT SYSTEMS INC is the larger business by last-quarter revenue ($311.7M vs $196.0M, roughly 1.6× Axsome Therapeutics, Inc.). COMMVAULT SYSTEMS INC runs the higher net margin — 4.7% vs -14.6%, a 19.3% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 13.3%). COMMVAULT SYSTEMS INC produced more free cash flow last quarter ($131.8M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 17.8%).

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.

Commvault Systems, Inc. is an American publicly traded cybersecurity and data protection software company. Commvault's services are used for data security, as well as cloud and infrastructure management.

AXSM vs CVLT — Head-to-Head

Bigger by revenue
CVLT
CVLT
1.6× larger
CVLT
$311.7M
$196.0M
AXSM
Growing faster (revenue YoY)
AXSM
AXSM
+51.7% gap
AXSM
65.0%
13.3%
CVLT
Higher net margin
CVLT
CVLT
19.3% more per $
CVLT
4.7%
-14.6%
AXSM
More free cash flow
CVLT
CVLT
$150.6M more FCF
CVLT
$131.8M
$-18.7M
AXSM
Faster 2-yr revenue CAGR
AXSM
AXSM
Annualised
AXSM
61.7%
17.8%
CVLT

Income Statement — Q4 FY2025 vs Q4 FY2026

Metric
AXSM
AXSM
CVLT
CVLT
Revenue
$196.0M
$311.7M
Net Profit
$-28.6M
$14.6M
Gross Margin
81.4%
Operating Margin
-13.8%
5.3%
Net Margin
-14.6%
4.7%
Revenue YoY
65.0%
13.3%
Net Profit YoY
61.9%
EPS (diluted)
$-0.55
$0.34

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AXSM
AXSM
CVLT
CVLT
Q1 26
$311.7M
Q4 25
$196.0M
$313.8M
Q3 25
$171.0M
$276.2M
Q2 25
$150.0M
$282.0M
Q1 25
$121.5M
$275.0M
Q4 24
$118.8M
$262.6M
Q3 24
$104.8M
$233.3M
Q2 24
$87.2M
$224.7M
Net Profit
AXSM
AXSM
CVLT
CVLT
Q1 26
$14.6M
Q4 25
$-28.6M
$17.8M
Q3 25
$-47.2M
$14.7M
Q2 25
$-48.0M
$23.5M
Q1 25
$-59.4M
$31.0M
Q4 24
$-74.9M
$11.0M
Q3 24
$-64.6M
$15.6M
Q2 24
$-79.3M
$18.5M
Gross Margin
AXSM
AXSM
CVLT
CVLT
Q1 26
81.4%
Q4 25
81.1%
Q3 25
80.1%
Q2 25
82.0%
Q1 25
82.6%
Q4 24
81.5%
Q3 24
81.6%
Q2 24
82.3%
Operating Margin
AXSM
AXSM
CVLT
CVLT
Q1 26
5.3%
Q4 25
-13.8%
6.3%
Q3 25
-27.0%
4.5%
Q2 25
-24.5%
8.9%
Q1 25
-46.9%
9.7%
Q4 24
-61.1%
5.2%
Q3 24
-59.8%
6.4%
Q2 24
-89.5%
8.2%
Net Margin
AXSM
AXSM
CVLT
CVLT
Q1 26
4.7%
Q4 25
-14.6%
5.7%
Q3 25
-27.6%
5.3%
Q2 25
-32.0%
8.3%
Q1 25
-48.9%
11.3%
Q4 24
-63.1%
4.2%
Q3 24
-61.7%
6.7%
Q2 24
-91.0%
8.2%
EPS (diluted)
AXSM
AXSM
CVLT
CVLT
Q1 26
$0.34
Q4 25
$-0.55
$0.40
Q3 25
$-0.94
$0.33
Q2 25
$-0.97
$0.52
Q1 25
$-1.22
$0.68
Q4 24
$-1.54
$0.24
Q3 24
$-1.34
$0.35
Q2 24
$-1.67
$0.41

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AXSM
AXSM
CVLT
CVLT
Cash + ST InvestmentsLiquidity on hand
$322.9M
$900.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$88.3M
$7.5M
Total Assets
$689.8M
$1.9B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AXSM
AXSM
CVLT
CVLT
Q1 26
$900.0M
Q4 25
$322.9M
$1.0B
Q3 25
$325.3M
$1.1B
Q2 25
$303.0M
$363.2M
Q1 25
$300.9M
$302.1M
Q4 24
$315.4M
$243.6M
Q3 24
$327.3M
$303.1M
Q2 24
$315.7M
$287.9M
Stockholders' Equity
AXSM
AXSM
CVLT
CVLT
Q1 26
$7.5M
Q4 25
$88.3M
$216.7M
Q3 25
$73.7M
$210.5M
Q2 25
$73.1M
$364.7M
Q1 25
$53.2M
$325.1M
Q4 24
$57.0M
$287.8M
Q3 24
$92.9M
$277.8M
Q2 24
$102.9M
$281.8M
Total Assets
AXSM
AXSM
CVLT
CVLT
Q1 26
$1.9B
Q4 25
$689.8M
$2.0B
Q3 25
$669.3M
$1.9B
Q2 25
$639.8M
$1.2B
Q1 25
$596.7M
$1.1B
Q4 24
$568.5M
$1.0B
Q3 24
$561.5M
$958.5M
Q2 24
$548.2M
$934.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AXSM
AXSM
CVLT
CVLT
Operating Cash FlowLast quarter
$-18.7M
$132.2M
Free Cash FlowOCF − Capex
$-18.7M
$131.8M
FCF MarginFCF / Revenue
-9.6%
42.3%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
9.02×
TTM Free Cash FlowTrailing 4 quarters
$-93.9M
$237.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AXSM
AXSM
CVLT
CVLT
Q1 26
$132.2M
Q4 25
$-18.7M
$4.0M
Q3 25
$1.0M
$76.8M
Q2 25
$-32.4M
$31.7M
Q1 25
$-43.4M
$77.0M
Q4 24
$-26.2M
$30.1M
Q3 24
$-18.6M
$55.6M
Q2 24
$-30.1M
$44.7M
Free Cash Flow
AXSM
AXSM
CVLT
CVLT
Q1 26
$131.8M
Q4 25
$-18.7M
$1.9M
Q3 25
$988.0K
$73.6M
Q2 25
$-32.4M
$29.8M
Q1 25
$-43.7M
$76.2M
Q4 24
$-26.2M
$29.9M
Q3 24
$-18.7M
$53.7M
Q2 24
$-30.2M
$43.8M
FCF Margin
AXSM
AXSM
CVLT
CVLT
Q1 26
42.3%
Q4 25
-9.6%
0.6%
Q3 25
0.6%
26.6%
Q2 25
-21.6%
10.6%
Q1 25
-36.0%
27.7%
Q4 24
-22.1%
11.4%
Q3 24
-17.9%
23.0%
Q2 24
-34.6%
19.5%
Capex Intensity
AXSM
AXSM
CVLT
CVLT
Q1 26
Q4 25
0.0%
0.7%
Q3 25
0.0%
1.2%
Q2 25
0.0%
0.7%
Q1 25
0.3%
0.3%
Q4 24
0.0%
0.1%
Q3 24
0.1%
0.8%
Q2 24
0.1%
0.4%
Cash Conversion
AXSM
AXSM
CVLT
CVLT
Q1 26
9.02×
Q4 25
0.23×
Q3 25
5.21×
Q2 25
1.35×
Q1 25
2.48×
Q4 24
2.74×
Q3 24
3.57×
Q2 24
2.41×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AXSM
AXSM

Segment breakdown not available.

CVLT
CVLT

Term-based license$114.4M37%
Software-as-a-service$93.1M30%
Customer support$80.9M26%
Other$13.1M4%
Perpetual license$10.1M3%

Related Comparisons